Cross-talk between amyloidogenic proteins in type-2 diabetes and Parkinson’s disease

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  2016-10-17

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1073/pnas.1610371113PMID 27791129PMCID PMC5098634
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Protein Partners of α‐Synuclein in Health and Disease

  2016cited by this paper
• Amylin alters human brain pericyte viability and NG2 expression

  2016cited by this paper
• Solid-State NMR Structure of a Pathogenic Fibril of Full-Length Human α-Synuclein

  2016cited by this paper
• Key Points Concerning Amyloid Infectivity and Prion-Like Neuronal Invasion

  2016cited by this paper
• Bacterial Chaperones CsgE and CsgC Differentially Modulate Human α-Synuclein Amyloid Formation via Transient Contacts

  2015cited by this paper
• α-Synuclein strains cause distinct synucleinopathies after local and systemic administration

  2015cited by this paper
• Insulin-degrading enzyme prevents α-synuclein fibril formation in a nonproteolytical manner

  2015cited by this paper
• In vivo seeding and cross-seeding of localized amyloidosis: a molecular link between type 2 diabetes and Alzheimer disease.

  2015cited by this paper
• Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration.

  2015cited by this paper
• Insulin-degrading enzyme is activated by the C-terminus of α-synuclein.

  2015cited by this paper
• The Ability of Insulin To Inhibit the Formation of Amyloid by Pro-Islet Amyloid Polypeptide Processing Intermediates Is Significantly Reduced in the Presence of Sulfated Glycosaminoglycans

  2014cited by this paper
• Differences between amyloid-β aggregation in solution and on the membrane: insights into elucidation of the mechanistic details of Alzheimer's disease.

  2014cited by this paper
• Defining the Molecular Basis of Amyloid Inhibitors: Human Islet Amyloid Polypeptide–Insulin Interactions

  2014cited by this paper
• Neuroinflammation and neurologic deficits in diabetes linked to brain accumulation of amylin

  2014cited by this paper
• In Search of Aggregation Pathways of IAPP and Other Amyloidogenic Proteins: Finding Answers through NMR Spectroscopy.

  2014cited by this paper
• System-based approaches to decode the molecular links in Parkinson's disease and diabetes.

  2014cited by this paper
• Walking deficits and centrophobism in an α-synuclein fly model of Parkinson's disease1

  2014cited by this paper
• Amylin deposition in the brain: A second amyloid in Alzheimer disease?

  2013cited by this paper
• Lipid bilayers significantly modulate cross-fibrillation of two distinct amyloidogenic peptides.

  2013cited by this paper
• Aggregation of islet amyloid polypeptide: from physical chemistry to cell biology.

  2013cited by this paper
• Cross-Seeding of Misfolded Proteins: Implications for Etiology and Pathogenesis of Protein Misfolding Diseases

  2013cited by this paper
• The Type 2 Diabetes–Associated Gene Ide Is Required for Insulin Secretion and Suppression of α-Synuclein Levels in β-Cells

  2013influential reference
• Cross-amyloid interaction of Aβ and IAPP at lipid membranes.

  2012cited by this paper
• Islet amyloid: From fundamental biophysics to mechanisms of cytotoxicity

  2012cited by this paper
• Membrane disruption and early events in the aggregation of the diabetes related peptide IAPP from a molecular perspective.

  2012cited by this paper
• Pathological α-Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice

  2012cited by this paper
• Misfolded proteins in Alzheimer's disease and type II diabetes.

  2012cited by this paper
• α-Synuclein binds the K(ATP) channel at insulin-secretory granules and inhibits insulin secretion.

  2011cited by this paper
• Diabetes and Risk of Parkinson’s Disease

  2011cited by this paper
• Mechanisms of Hybrid Oligomer Formation in the Pathogenesis of Combined Alzheimer's and Parkinson's Diseases

  2008cited by this paper
• Nano-scale imaging and dynamics of amylin-membrane interactions and its implication in type II diabetes mellitus.

  2008cited by this paper
• Genome-Wide Association Analysis Identifies Loci for Type 2 Diabetes and Triglyceride Levels

  2007cited by this paper
• Neuropathology, biochemistry, and biophysics of α‐synuclein aggregation

  2007cited by this paper
• WSXM: a software for scanning probe microscopy and a tool for nanotechnology.

  2007cited by this paper
• Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation.

  2007cited by this paper
• Impaired NH2-Terminal Processing of Human Proislet Amyloid Polypeptide by the Prohormone Convertase PC2 Leads to Amyloid Formation and Cell Death

  2006influential reference
• Structural characterisation of islet amyloid polypeptide fibrils.

  2004cited by this paper
• Seeding Specificity in Amyloid Growth Induced by Heterologous Fibrils*

  2004cited by this paper
• Pancreatic beta-cell granule peptides form heteromolecular complexes which inhibit islet amyloid polypeptide fibril formation.

  2004influential reference
• Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo

  2003cited by this paper
• Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease.

  2003cited by this paper
• Part II: α-synuclein and its molecular pathophysiological role in neurodegenerative disease

  2003cited by this paper
• Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo.

  2003cited by this paper
• Dopamine-dependent neurotoxicity of α-synuclein: A mechanism for selective neurodegeneration in Parkinson disease

  2002cited by this paper
• Golgi Fragmentation Occurs in the Cells with Prefibrillar α-Synuclein Aggregates and Precedes the Formation of Fibrillar Inclusion*

  2002cited by this paper
• Conformational properties of alpha-synuclein in its free and lipid-associated states.

  2001cited by this paper
• Islet Amyloid Development in a Mouse Strain Lacking Endogenous Islet Amyloid Polypeptide (IAPP) but Expressing Human IAPP

  2000cited by this paper
• Amyloidogenicity of recombinant human pro-islet amyloid polypeptide (ProIAPP).

  2000cited by this paper
• Insulin degradation: progress and potential.

  1998cited by this paper
• Alpha-synuclein in Lewy bodies.

  1997cited by this paper
• Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.

  1997cited by this paper
• Polymorphic fibrillar assembly of human amylin.

  1997cited by this paper
• Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease

  1997cited by this paper
• The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system

  1995cited by this paper
• Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal

  1988cited by this paper
• A high molecular weight metalloendoprotease from the cytosol of mammalian cells.

  1983cited by this paper
• Supporting Online Material Materials and Methods Figs. S1 to S8 Tables S1 to S10 References a Genome-wide Association Study of Type 2 Diabetes in Finns Detects Multiple Susceptibility Variants

  year unknowninfluential reference

• The impact of diabetes mellitus in prodromal Parkinson’s disease

  2026cites this paper
• Association of long-term glycemic variability with longitudinal motor and nonmotor progression in patients with Parkinson's disease: an 8-year follow-up.

  2025cites this paper
• Electronic effect of (E)-1-(2-hydroxyphenyl)-3-phenylprop-2-en-1-one derivatives on the promotion and modulation of the aggregation of bovine beta-lactoglobulin

  2025cites this paper
• Multi-Targeting Macrocyclic Peptides as Nanomolar Inhibitors of Self- and Cross-Seeded Amyloid Self-Assembly of α-Synuclein.

  2025cites this paper
• Parkinson's disease and brain insulin signaling: Mechanisms and potential role of GLP-1 mimetics.

  2025cites this paper
• Antimicrobial peptides and proteins in Alzheimer’s and Parkinson’s diseases: implications for biomarker exploration

  2025cites this paper
• Evaluating the Molecular Interactions between Type 2 Diabetes Mellitus and Parkinson's Disease: Role of Antidiabetic Drugs as Promising Therapeutics.

  2025cites this paper
• Interactions between pathological and functional amyloid: A match made in Heaven or Hell?

  2025cites this paper
• The deposition and cross-seeding of islet amyloid polypeptide and phosphorylated α-Synuclein in gut, myocardium, and brain of cynomolgus monkeys with spontaneous type 2 diabetes mellitus

  2025cites this paper
• Impact of diabetes mellitus type two on incidence and progression of Parkinson’s disease: a systematic review of longitudinal patient cohorts

  2025cites this paper
• The role of amylin, a gut–brain axis hormone, in metabolic and neurological disorders

  2025cites this paper
• Unraveling α-synuclein and amylin co-aggregation: pathological insights and biomarker development for Parkinson's disease

  2025cites this paper
• Phase Separation Regulates Metabolism, Mitochondria, and Diseases

  2025cites this paper
• Mechanisms of IGF1R signaling in type 2 diabetes-related neurodegeneration and therapeutic implications of exercise

  2025cites this paper
• Cell-to-cell transmission of IAPP aggregates in T2DM induces neuronal death by triggering oxidative stress and ferroptosis.

  2025cites this paper
• Nanocarriers to mediate the pathways from diabetes toward Parkinson's disease

  2024cites this paper
• The Inhibition Effect of Epigallocatechin-3-Gallate on the Co-Aggregation of Amyloid-β and Human Islet Amyloid Polypeptide Revealed by Replica Exchange Molecular Dynamics Simulations

  2024cites this paper
• The comorbidity profiles and medication issues of patients with multiple system atrophy: a systematic cross-sectional analysis

  2024cites this paper
• The causal relationship between type 2 diabetes mellitus and isolated REM sleep behavior disorder: results from multivariable and network Mendelian randomization analysis

  2024cites this paper
• The Interplay of Stress, Inflammation, and Metabolic Factors in the Course of Parkinson’s Disease

  2024cites this paper
• Exploring the therapeutic potential of Chinese herbs on comorbid type 2 diabetes mellitus and Parkinson's disease: A mechanistic study.

  2024cites this paper
• Increased dementia risk in patients with Parkinson’s disease attributed to metabolic syndrome

  2024cites this paper
• Shiitake-derived lentinan prevents α-synuclein aggregation, disassembles amyloid aggregates, and protects dopaminergic neurons

  2024cites this paper
• Islet amyloid polypeptide fibril catalyzes amyloid-β aggregation by promoting fibril nucleation rather than direct axial growth.

  2024cites this paper
• Exploring pathological link between antimicrobial and amyloid peptides.

  2024cites this paper
• Proteomic Evidence for Amyloidogenic Cross-Seeding in Fibrinaloid Microclots

  2024cites this paper
• Promotion and modulation of amyloid fibrillation of bovine beta-lactoglobulin by hydroxychalcones

  2024cites this paper
• Unraveling the Ties: Type 2 Diabetes and Parkinson's Disease - A Nano-Based Targeted Drug Delivery Approach.

  2024cites this paper
• Mechanistic Insights Behind the Self-Assembly of Human Insulin under the Influence of Surface-Engineered Gold Nanoparticles

  2024cites this paper
• The Contribution of Type 2 Diabetes to Parkinson’s Disease Aetiology

  2024cites this paper
• Understanding the link between type 2 diabetes mellitus and Parkinson’s disease: role of brain insulin resistance

  2024cites this paper
• Les dépôts amyloïdes dans les îlots de Langerhans, fonctions pathologiques et cibles thérapeutiques

  2024cites this paper
• Studies on alpha-synuclein and islet amyloid polypeptide interaction

  2023cites this paper
• Nucleation of α-Synuclein Amyloid Fibrils Induced by Cross-Interaction with β-Hairpin Peptides Derived from Immunoglobulin Light Chains

  2023cites this paper
• Association between falls and nonmotor symptoms in patients with Parkinson's disease.

  2023cites this paper
• The yeast prion protein Sup35 initiates α-synuclein pathology in mouse models of Parkinson’s disease

  2023cites this paper
• Thiadiazolidinone (TDZD) Analogs Inhibit Aggregation-Mediated Pathology in Diverse Neurodegeneration Models, and Extend C. elegans Life- and Healthspan

  2023cites this paper
• Interaction of Proteins Involved in Neuronal Proteinopathies

  2023influential citation
• An Innate Host Defense Protein; β2-Microglobulin Keeps a Check on α-Synuclein Amyloid Assembly: Implications in Parkinson's disease.

  2023cites this paper
• The Aβ42 Peptide and IAPP Physically Interact in a Yeast-Based Assay

  2023cites this paper
• Brain Hydrophobic Peptides Antagonists of Neurotoxic Amyloid β Peptide Monomers/Oligomers–Protein Interactions

  2023cites this paper
• Are fibrinaloid microclots a cause of autoimmunity in Long Covid and other post-infection diseases?

  2023cites this paper
• How should we be using biomarkers in trials of disease modification in Parkinson’s disease?

  2023cites this paper
• Perturbation of surfactant-induced amyloids by abolishing electrostatic interactions

  2023cites this paper
• Melatonin as a Chronobiotic/Cytoprotective Agent in REM Sleep Behavior Disorder

  2023cites this paper
• Condensation of the β‐cell secretory granule luminal cargoes pro/insulin and ICA512 RESP18 homology domain

  2023cites this paper
• Islet Amyloid Polypeptide Triggers α-synuclein Pathology in Parkinson's Disease.

  2023cites this paper
• Type 2 Diabetes (T2DM) and Parkinson’s Disease (PD): a Mechanistic Approach

  2023cites this paper
• Recent advances in the modulation of amyloid protein aggregation using the supramolecular host-guest approaches.

  2023cites this paper
• PPARs and Their Neuroprotective Effects in Parkinson’s Disease: A Novel Therapeutic Approach in α-Synucleinopathy?

  2023cites this paper
• Cysteine-Derived Chiral Carbon Quantum Dots: A Fibrinolytic Activity Regulator for Plasmin to Target the Human Islet Amyloid Polypeptide for Type 2 Diabetes Mellitus.

  2023cites this paper
• Targeting hIAPP fibrillation: A new paradigm to prevent β-cell death?

  2022cites this paper
• Type 2 Diabetes and Parkinson's Disease: A Focused Review of Current Concepts

  2022cites this paper
• Amyloid Protein Cross-Seeding Provides a New Perspective on Multiple Diseases In Vivo.

  2022cites this paper
• Recent research progress on metabolic syndrome and risk of Parkinson’s disease

  2022cites this paper
• Association between prediabetes and cognitive function in Parkinson's disease

  2022cites this paper
• Association between Parkinson’s Disease and Diabetes Mellitus: From Epidemiology, Pathophysiology and Prevention to Treatment

  2022cites this paper
• Type 2 diabetes mellitus augments Parkinson's disease risk or the other way around: facts, challenges and future possibilities.

  2022cites this paper
• Mechanisms behind the Fibrillation and Toxicity of Insulin Fibrils on Neuron Cells by Engineered Curcumin Analogs.

  2022cites this paper
• Exposure to the environmentally toxic pesticide maneb induces Parkinson's disease-like neurotoxicity in mice: A combined proteomic and metabolomic analysis.

  2022cites this paper
• Computational design of a β-wrapin's N-terminal domain with canonical and non-canonical amino acid modifications mimicking curcumin's proposed inhibitory function.

  2022cites this paper
• Linking Alzheimer’s Disease and Type 2 Diabetes: Characterization and Inhibition of Cytotoxic Aβ and IAPP Hetero-Aggregates

  2022cites this paper
• Nutrient‐sensing amyloid metastasis

  2022cites this paper
• Molecular Mechanisms of Amylin Turnover, Misfolding and Toxicity in the Pancreas

  2022cites this paper
• Parkinson’s disease and diabetes mellitus: common mechanisms and treatment repurposing

  2022cites this paper
• Crossroads between copper ions and amyloid formation in Parkinson’s disease

  2022cites this paper
• Linking hIAPP misfolding and aggregation with type 2 diabetes mellitus: a structural perspective

  2022cites this paper
• Role of Liquid–Liquid Separation in Endocrine and Living Cells

  2021cites this paper
• Proteostasis of Islet Amyloid Polypeptide: A Molecular Perspective of Risk Factors and Protective Strategies for Type II Diabetes.

  2021cites this paper
• Synergistic Effects of Milk-Derived Exosomes and Galactose on α-Synuclein Pathology in Parkinson’s Disease and Type 2 Diabetes Mellitus

  2021cites this paper
• Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer's Disease, Parkinson's Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis.

  2021cites this paper
• Mechanistic Insights into the Co-Aggregation of Aβ and hIAPP: An All-Atom Molecular Dynamic Study.

  2021cites this paper
• Type 2 Diabetes as a Determinant of Parkinson’s Disease Risk and Progression

  2021cites this paper
• Diabetes, insulin and new therapeutic strategies for Parkinson's disease: focus on glucagon-like peptide-1 receptor agonists.

  2021cites this paper
• Melatonin as a Chronobiotic and Cytoprotective Agent in Parkinson’s Disease

  2021cites this paper
• Faster disease progression in Parkinson’s disease with type 2 diabetes is not associated with increased α‐synuclein, tau, amyloid‐β or vascular pathology

  2021cites this paper
• Self-assembled fibrinogen–fibronectin hybrid protein nanofibers with medium-sensitive stability

  2021cites this paper
• Necessity of regulatory guidelines for the development of amyloid based biomaterials.

  2021cites this paper
• Linking Parkinson's Disease and Melanoma: Interplay Between α‐Synuclein and Pmel17 Amyloid Formation

  2021cites this paper
• Living with the enemy: from protein-misfolding pathologies we know, to those we want to know.

  2021cites this paper
• Prediabetes, type 2 diabetes mellitus and risk of Parkinson's disease: A population-based cohort study.

  2021cites this paper
• Challenges in sample preparation and structure determination of amyloids by cryo-EM

  2021cites this paper
• Macromolecular crowding modulates α-synuclein amyloid fiber growth

  2021cites this paper
• β-Hairpin Peptide Mimics Decrease Human Islet Amyloid Polypeptide (hIAPP) Aggregation

  2021cites this paper
• Islet amyloid toxicity: From genesis to counteracting mechanisms

  2021cites this paper
• Insulin-releasing or insulin-sensitizing drugs in Parkinson's disease? Choosing a pathway.

  2021cites this paper
• The Impact of Type 2 Diabetes in Parkinson's Disease

  2021cites this paper
• A new strategy to reconcile amyloid cross‐seeding and amyloid prevention in a binary system of α‐synuclein fragmental peptide and hIAPP

  2021cites this paper
• Cynomolgus Monkeys With Spontaneous Type-2-Diabetes-Mellitus-Like Pathology Develop Alpha-Synuclein Alterations Reminiscent of Prodromal Parkinson’s Disease and Related Diseases

  2020cites this paper
• Glycation of glyceraldehyde-3-phosphate dehydrogenase inhibits the binding with α-synuclein and RNA.

  2020cites this paper
• Biophysical processes underlying cross-seeding in amyloid aggregation and implications in amyloid pathology.

  2020cites this paper
• α-Synuclein promotes IAPP fibril formation in vitro and β-cell amyloid formation in vivo in mice

  2020cites this paper
• PRION PROTEINS AND DIABETES MELLITUS - A REVIEW

  2020cites this paper
• The Human Islet Amyloid Polypeptide in Protein Misfolding Disorders: Mechanisms of Aggregation and Interaction with Biomembranes.

  2020cites this paper
• Novel protein and peptide nanofibrous structures via supramolecular co-assembly

  2020cites this paper
• Type 2 diabetes as a determinant of Parkinson's disease risk and progression.

  2020cites this paper
• Implications of the Human Gut-Brain and Gut-Cancer Axes for Future Nanomedicine.

  2020cites this paper
• Characterization of insulin cross-seeding: the underlying mechanism reveals seeding and denaturant-induced insulin fibrillation proceeds through structurally similar intermediates

  2020cites this paper
• Inhibitory effect of coumarin and its analogs on insulin fibrillation /cytotoxicity is depend on oligomerization states of the protein

  2020cites this paper
• Enlightening amyloid fibrils linked to type 2 diabetes and cross-interactions with Aβ

  2020cites this paper